

June 16, 2015



## **SPECIAL EVENT: “Geraldo Rivera Show” to Feature AxoGen, Inc. CEO Karen Zaderej on Helping Our Injured Military Members – First in a Series of Three Interviews**

**Interview Airs June 16, 2015, Host Geraldo Rivera, 10:52 AM ET | 9:52 AM CT | 7:52 AM PT**

**ALACHUA, FL, June 16, 2015** – AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Chief Executive Officer Karen Zaderej will be interviewed in a special three-day Q&A miniseries on “Geraldo Rivera Show,” hosted by Geraldo Rivera and broadcasted on 77 WABC from New York City. In the first of this three segment exclusive interview, Geraldo will discuss how AxoGen works to help military personnel with nerve injuries repaired with its processed human nerve allograft, Avance® Nerve Graft.

All shareholders, analysts, industry professionals, health care providers and anyone experiencing symptoms of a nerve injury are encouraged to listen to the broadcast to learn more about options in nerve repair. Broadcast details for the first of three segments are as follows:

**Date:** Tuesday, June 16, 2015

**Start Time:** 10:52 AM ET | 9:52 AM CT | 7:52 AM PT

**Network:** WABC

**Station:** [770 AM, 77WABC Radio](#)

**Show:** [“Geraldo Rivera Show”](#)

**Host:** Geraldo Rivera

### **About Geraldo Rivera**

Geraldo Rivera: A three-time recipient of the 2000 Robert F. Kennedy journalism award. He has received more than 170 awards for journalism, including the prestigious George Foster Peabody Award, three national and seven local Emmys, two Columbia-Dupont and two additional Scripps Howard Journalism Awards. Rivera is a graduate of the University of Arizona and Brooklyn Law School and is the author of seven books. [www.geraldo.com/](http://www.geraldo.com/) | <http://www.wabcradio.com/geraldorivera/>

## **About AxoGen, Inc.**

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance<sup>®</sup> Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard<sup>®</sup> Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard<sup>®</sup> Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

To learn more about AxoGen and to sign up for news alerts, visit [www.AxoGenInc.com](http://www.AxoGenInc.com).

## **Cautionary Statement Concerning Forward-Looking Statements**

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

### **Company Contact:**

#### **AxoGen, Inc.**

Lee Robert "Bob" Johnston, Chief Financial Officer

(P) 386.462.6856

[InvestorRelations@AxoGenInc.com](mailto:InvestorRelations@AxoGenInc.com)

[www.axogeninc.com](http://www.axogeninc.com)

### **Interview / Media Contact:**

Matthew BIRD, President

1-800-PublicRelations, Inc.

(P) 646.401.4499

(O) 800.782.6185

[matt.bird@1800pr.com](mailto:matt.bird@1800pr.com)

[www.1800pr.com](http://www.1800pr.com)